vTv jumps after FDA lifts clinical hold on diabetes therapy

Shares of drug developer vTv Therapeutics VTVT.O rise 19.2% to $17.70, their biggest one-day percentage win in more than one year

Co says U.S. FDA has lifted clinical hold on development of cadisegliatin, an oral adjunctive therapy to insulin therapy for treatment of type 1 diabetes

Co plans to resume its late-stage trial for the therapy after submitting protocol amendment to shorten trial from 12 to 6 months

Up to last close, stock down 12.9% in last 12 months